Ovid Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

OVID$2.80-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

(in thousands, except shares) · Series AConvertiblePreferred Stock · Common Stock · AdditionalPaid-In Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total
Shares · Amount · Shares · Amount
Balance, December 31, 2023	1,250		$—		70,691,992		$71		$365,591	$1	$(277,866)	$87,797
Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan	—		—		91,969		—		228	—	—	228
Stock-based compensation expense	—		—		—		—		1,968	—	—	1,968
Other comprehensive loss	—		—		—		—		—	(20)	—	(20)
Net loss	—		—		—		—		—	—	(11,694)	(11,694)
Balance, March 31, 2024	1,250		$—		70,783,961		$71		$367,787	(19)	$(289,560)	$78,279
Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan	—		—		187,616		—		356	—	—	356
Stock-based compensation expense	—		—		—		—		1,740	—	—	1,740
Other comprehensive income	—		—		—		—		—	7	—	7
Net income	—		—		—		—		—	—	8,521	8,521
Balance, June 30, 2024	1,250		$—		70,971,577		$71		$369,883	$(12)	$(281,039)	$88,903
Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan	—		—		38,289		—		37	—	—	38
Stock-based compensation expense	—		—		—		—		1,307	—	—	1,307
Other comprehensive income	—		—		—		—		—	48	—	48
Net loss	—		—		—		—		—	—	(14,006)	(14,006)
Balance, September 30, 2024	1,250		$—		71,009,866		$71		$371,228	$36	$(295,045)	$76,290
(in thousands, except shares)	Series AConvertiblePreferred Stock	Common Stock		AdditionalPaid-In Capital	AccumulatedOtherComprehensive (Loss) Income	Accumulated Deficit		Total
Shares · Amount · Shares · Amount
Balance, December 31, 2022	1,250		$—		70,466,885		$70		$357,771	$(42)	$(225,527)	$132,273
Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan	—		—		24,625		—		67	—	—	67
Stock-based compensation expense	—		—		—		—		1,917	—	—	1,917
Other comprehensive income	—		—		—		—		—	48	—	48
Net loss	—		—		—		—		—	—	(13,356)	(13,356)
Balance, March 31, 2023	1,250		$—		70,491,510		$70		$359,755	6	$(238,883)	$120,948
Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan	—		—		112,283		—		211	—	—	211
Stock-based compensation expense	—		—		—		—		1,949	—	—	1,949
Other comprehensive loss	—		—		—		—		—	—	—	—
Net loss	—		—		—		—		—	—	(12,408)	(12,408)
Balance, June 30, 2023	1,250		$—		70,603,793		$71		$361,915	$6	$(251,291)	$110,701
Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan	—		—		76,758		—		224	—	—	224
Stock-based compensation expense	—		—		—		—		1,631	—	—	1,631
Other comprehensive loss	—		—		—		—		—	(9)	—	(9)
Net loss	—		—		—		—		—	—	(11,253)	(11,253)
Balance, September 30, 2023	1,250		$—		70,680,551		$71		$363,770	$(3)	$(262,544)	$101,294

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.